Shares of Urogen Pharma (NASDAQ:URGN) have been assigned an average broker rating score of 1.25 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.

Brokers have set a one year consensus price objective of $31.33 for the company and are forecasting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Urogen Pharma an industry rank of 159 out of 265 based on the ratings given to its competitors.

Several research analysts have recently commented on the company. Jefferies Group LLC boosted their price objective on Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Monday. Zacks Investment Research downgraded Urogen Pharma from a “hold” rating to a “sell” rating in a report on Thursday, September 14th. Finally, Oppenheimer Holdings, Inc. set a $32.00 price objective on Urogen Pharma and gave the stock a “buy” rating in a report on Monday, August 14th.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Urogen Pharma (URGN) to Post ($0.05) EPS” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/analysts-anticipate-urogen-pharma-urgn-to-post-0-05-eps/1626716.html.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wildcat Capital Management LLC bought a new stake in Urogen Pharma in the 2nd quarter worth approximately $2,439,000. Hillhouse Capital Management Ltd. purchased a new position in shares of Urogen Pharma in the 2nd quarter worth approximately $6,363,000. FMR LLC purchased a new position in shares of Urogen Pharma in the 2nd quarter worth approximately $13,892,000. Jennison Associates LLC purchased a new position in shares of Urogen Pharma in the 2nd quarter worth approximately $3,168,000. Finally, Alps Advisors Inc. purchased a new position in shares of Urogen Pharma in the 2nd quarter worth approximately $195,000. 36.06% of the stock is currently owned by institutional investors.

Shares of Urogen Pharma (NASDAQ:URGN) traded down 2.8621% during midday trading on Friday, reaching $29.8699. 11,196 shares of the company’s stock were exchanged. Urogen Pharma has a 12 month low of $13.01 and a 12 month high of $33.77. The firm has a 50 day moving average price of $28.32 and a 200 day moving average price of $20.91. The company’s market cap is $388.58 million.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.